Sepsis
Conditions
Brief summary
In the REMISE is study, we will compare blood proteins, biomarkers, and other -omics prospectively collected from patients with sepsis from two sources, i.) remnant (discarded) samples from the clinical laboratory, and ii.) prospectively collected in UPMC Presbyterian hospital research coordinator specimen collected biospecimens. Analyses will include traditional biomarkers, quantitative proteomics, metabolomics, lipidomics, transcriptomics, and pathogen genomic sequencing in both sets of samples. This data will allow the assessment of the feasibility, integrity, and scientific value of remnant samples compared to research coordinator samples collected at the bedside for mechanistic sepsis research.
Interventions
None listed
Sponsors
Vanderbilt University
National Institute of General Medical Sciences (NIGMS)
University of Pittsburgh
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patient, at least 18 years of age * Meeting Sepsis-3 criteria within 6 hours of admission * Biospecimens obtained for routine clinical care and measurement * Peripheral intravenous access
Exclusion criteria
* Patients who do not have Sepsis-3 * Traumatic injury, * Inability to consent or contact legal representative, * Cardiac arrest, * Stroke, * Comfort measures only, * Unable to obtain intravenous access, and/or * Subject declines to participate. * No residual blood left in clinical sample
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in traditional biomarkers, proteomics, pathogen sequencing, and metabolomics/lipidomics between prospectively collected biospecimens and remnant biospecimens. | 01/2024 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of traditional biomarkers in all samples | 1/2024 | Traditional biomarkers to be measured in remnant and research specimens including inflammatory and endothelial-related biomarkers. |
| Measurement of proteomics in all samples | 1/2024 | Proteomics to be measured in remnant and research specimens to capture over 50 different plasma proteins. |
| Measurement of metabolomics/lipidomics in all samples | 1/2024 | Metabolomics and lipidomics to be measured in remnant and research specimens to capture organic acids, amino acids, and phospholipids. |
| Pathogen sequencing in all samples | 1/2024 | Pathogen sequencing will be performed on all remnant and research specimens to precisely identify the causative strain(s) in the infection. |
Countries
United States
Outcome results
None listed